ArticleDiscover oncology2026
AHNAK2 exacerbates the malignant phenotype of gastric cancer through activation of the Wnt/β-catenin signaling pathway.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAHNAK2 is acknowledged to function as an oncoprotein that enhances the invasive and metastatic potential of tumor cells in multiple types of malignancy. Nevertheless, its specific role in gastric cancer (GC) remains unclear.
methodsImmunohistochemistry (IHC) was used to examine AHNAK2 expression in matched GC tissues and paracancerous tissues, Clinical and pathological data was gathered for the purpose of investigate the association of AHNAK2 expression and prognosis in patients with GC. AHNAK2 protein expression and location was examined using Western blotting (WB) and immunofluorescence (IF). The effects of AHNAK2 knockdown on the malignant biological behavior of GC cells were evaluated. Transcriptome sequencing and WB analyses were conducted to explore the potential molecular mechanisms underlying AHNAK2-mediated regulation of GC progression.
resultsWB, IF, and IHC analyses demonstrate that AHNAK2 expression is upregulated in GC, and patients with high AHNAK2 protein expression exhibit poorer overall survival rates. Knockdown of AHNAK2 results in reduced invasive, proliferative, and migratory capacities of GC cells, along with increased apoptosis. RNA sequencing and WB analysis further confirmed that AHNAK2 exacerbates the malignant phenotypic characteristics of GC through activation of the Wnt/β-catenin pathway.
conclusionAHNAK2 may serve as a new prognostic biomarker and a prospective therapeutic target in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.